Table 4. Hematologic response at 3 and 12 months after RA-SCT in 83 patients.
| Patients |
Time after SCT, n (%) |
|
|---|---|---|
| 3 months | 12 months | |
| All patients in phase 2 trials (n=83) | ||
| CR | 20 (24) | 40 (48) |
| Deceased/off study | 4 (5) | 10 (12) |
| Patients achieving CR by consolidation | ||
| Post-SCT TD consolidation (n=44) | 9 (21) | 16 (36) |
| Post-SCT BD consolidation (n=39) | 11 (28) | 24 (62) |
Abbreviations: BD, bortezomib and dexamethasone; CR, complete response; RA-SCT, stem cell transplantation and risk-adapted dosing of melphalan; SCT, stem cell transplantation; TD, thalidomide and dexamethasone.